All,
Preface:
As of 2024, Pro Medicus has been operating in the USA for 14 years, holding approximately 7% of the U.S. diagnostic imaging market. While this is a relatively small share, it presents substantial revenue and opportunities for growth, given the large addressable market. In the med-tech space, the landscape is competitive, often allowing for multiple winners in the market.Market Analysis - AI-Cardiological Diagnostics
From my research, there are several companies using AI-based decision-support systems to identify severe aortic stenosis (AS):
- Echo IQ
- Ultromics (EchoGo®)
- iCardio.ai
- AccurKardia
Additionally, several companies are using AI to identify heart failure (HF) with similar decision-support systems:
- Ultromics (EchoGo®)
- Echo IQ
- GE Healthcare
- Caption Health
Competitive Advantages
Echo IQ (EIQ) has the potential to build a sustainable competitive advantage in several areas:
Legal Advantages
a. Regulatory (FDA) Approval and Compliance
b. Proprietary TechnologyProduct Validation Advantages
a. Large clinical dataset of echocardiograms
b. A product that is more sophisticated and easier to use than competitors
c. Continuous innovation and reinvestment in R&D and product designStrong Partnerships and Collaborations
a. An experienced, US-based CEO who can leverage his network and commercialization experience to drive sales growth
b. A US-based CEO with extensive experience in delivering commercial outcomes across the med-tech sector
c. Long-term contracts
d. Strong customer support and education programsScalability and Adaptability
a. An efficient and scalable solution
b. Speed to market
c. Scalability and operational leverage
d. Cloud deploymentFinancial Advantages
a. Securing reimbursement codes
b. Pricing model advantages and monetization strategies
c. High switching costs for clients
d. Maintaining cost efficiencies, strong margins, and a financial position conducive to growthPotential Market Capitalization
As mentioned in the preface, Echo IQ does not need to dominate the market to generate significant revenue. If the company can capture just 5% of the 20 million echocardiograms performed annually in the U.S.over a 5-10 year period, it would result in an impressive return on investment (ROI) for its investors.
- Forums
- ASX - By Stock
- EIQ
- Competitive Landscape and Advantages
EIQ
echoiq limited
Add to My Watchlist
2.38%
!
21.5¢

Competitive Landscape and Advantages
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
21.5¢ |
Change
0.005(2.38%) |
Mkt cap ! $138.7M |
Open | High | Low | Value | Volume |
21.5¢ | 22.0¢ | 20.5¢ | $321.5K | 1.516M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 212563 | 21.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
22.0¢ | 400412 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 212563 | 0.215 |
2 | 223000 | 0.210 |
13 | 488968 | 0.205 |
14 | 423058 | 0.200 |
2 | 251538 | 0.195 |
Price($) | Vol. | No. |
---|---|---|
0.220 | 400412 | 5 |
0.225 | 156851 | 4 |
0.230 | 244729 | 7 |
0.235 | 170814 | 3 |
0.240 | 46211 | 2 |
Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
Featured News
EIQ (ASX) Chart |